MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment

NCT06177028 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Cognitive Impairment, Mild
Cognitive Dysfunction
Amyloid Plaque
Neurodegenerative Disease, Hereditary
Inflammation, Brain

Interventions

DRUG: Lenalidomide 10 mg

Sponsor

St. Joseph's Hospital and Medical Center, Phoenix

Collaborators

[object Object]